Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immucor -- Ignore unavailable to you. Want to Upgrade?

To: Bert Zed who wrote (376)	1/11/2000 10:22:00 PM
From: Thomas Kirwin	Respond to of 422

Consorta Awards Immucor Two National Contracts Tuesday January 11, 8:01 am Eastern Time Partnership Increases Immucor's Leadership Position in the U.S. Market Immucor to be Exclusive Blood Reagents Supplier to 264 Hospitals Nationwide Represents $1.9 Million in Increased Annual Revenues NORCROSS, Ga., Jan. 11 /PRNewswire/ -- Immucor, Inc. (Nasdaq: BLUD - news), the leading provider of blood bank reagents, instrumentation and related products in North America, today announced that it has been awarded two multi-year contracts with Consorta Catholic Resource Partners, Rolling Meadows, IL, the sixth largest health care Group Purchasing Organization in the United States. Under terms of the first agreement, which is effective February 1, 2000, Immucor will be the exclusive supplier to 264 hospitals represented by Consorta for traditional blood banking reagents for a period of three years with an option for a fourth year renewal by Consorta. This contract represents Immucor's initial business with Consorta and will increase Immucor's annual revenues by approximately $1.9 million. The second agreement, which is also effective February 1, 2000, gives Immucor access to place automated instrumentation and related reagents in those same hospitals. Previously Immucor was not permitted to place instrumentation in these hospitals. ''Immucor is pleased to become a business partner with Consorta,'' said, Edward L. Gallup, president and chief executive officer of Immucor. ''It further establishes Immucor's leadership position in the blood transfusion market by giving us the ability to offer our comprehensive line of products to every member of the top 10 Group Purchasing Organizations in the United States. More importantly, over 200 hospitals nationwide will now have the opportunity to improve blood safety for patients with our automated testing and tracking technology, as well as reduce time and labor costs.'' Founded in 1982, Immucor manufactures and sells a complete line of reagents and systems used by hospitals, reference laboratories and donor centers to detect and identify certain properties of the cell and serum components of blood prior to transfusion. Immucor markets a complete family of automated instrumentation for all of our market segments. For more information on Immucor, please visit the Company's website at immucor.com . This press release contains forward-looking statements as that term is defined in the Private Securities Reform Act of 1995, including, without limitation, statements concerning the Company's expectations, beliefs, intentions or strategies regarding the future. In particular, statements concerning future increases in sales and shareholder value are forward-looking statements, and it is not certain those things will occur. All forward- looking statements included in this document are based on information available to the Company on the date hereof, and the Company assumes no obligation to update any such forward-looking statements. Further risks are detailed in the Company's filings with the Securities and Exchange Commission, including those set forth in the Company's most recent Form 10-K and Quarterly Reports on Form 10-Q.

To: Bert Zed who wrote (376)	1/11/2000 10:55:00 PM
From: Thomas Kirwin	Read Replies (1) \| Respond to of 422

To Err is Human Date: Nov. 29, 1999 Contacts: Neil Tickner, Media Relations Officer Megan O'Neill, Media Relations Assistant (202) 334-2138; e-mail <news@nas.edu> FOR IMMEDIATE RELEASE Preventing Death and Injury From Medical Errors Requires Dramatic, System-Wide Changes WASHINGTON - Reducing one of the nation's leading causes of death and injury - medical errors - will require rigorous changes throughout the health care system, including mandatory reporting requirements, says a new report from the Institute of Medicine (IOM) of the National Academies. The report lays out a comprehensive strategy for government, industry, consumers, and health providers to reduce medical errors, and it calls on Congress to create a national patient safety center to develop new tools and systems needed to address persistent problems. The human cost of medical errors is high. Based on the findings of one major study, medical errors kill some 44,000 people in U.S. hospitals each year. Another study puts the number much higher, at 98,000. Even using the lower estimate, more people die from medical mistakes each year than from highway accidents, breast cancer, or AIDS. www4.nationalacademies.org To Err is Human: Building A Safer Health System books.nap.edu Best O'Luck, Tom